Fulgent Genetics Inc (FLGT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $688.98M
Last updated: Nov 17, 2026 at 4:30 PM ET
Fulgent Genetics Inc (FLGT) Statistics
Fulgent Genetics (FLGT) has a market cap of $688.98M and an enterprise value of $602.67M. Its share count is down 10.04% from a year earlier. It kept -27.85% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 12.53% below the market cap, as cash exceeds debt.
| Market Cap | $688.98M |
|---|---|
| Enterprise Value | $602.67M |
| Latest price (Nov 17, 2026) | $24.21 |
Key Dates
The next earnings report is expected on Feb 25, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 25, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.0x and 0.7x. Its year-end P/S ranged from 1.5x to 9.2x from 2016 to 2025.
| P/S Ratio | 2.0x |
|---|---|
| Forward P/S | 2.1x |
| P/B Ratio | 0.7x |
| P/TBV Ratio | 0.8x |
| P/OCF Ratio | 47.8x |
Price Statistics
The stock is down 16.80% over 52 weeks and trades 12.34% above its 50-day average.
| Beta (1Y) | 1.08 |
|---|---|
| 52-Week Change | -16.80% |
| 1-Month Change | +20.45% |
| 3-Month Change | +22.64% |
| 6-Month Change | +51.79% |
| 5-Year Change | -75.13% |
| 10-Year Change | +129.11% |
| Total Return (1Y) | -16.80% |
| Total Return (3Y CAGR) | -3.64% |
| Total Return (5Y CAGR) | -23.70% |
| Return vs SPY (1Y) | -28.36% |
| Max Drawdown (1Y) | -55.30% |
| Max Drawdown (3Y) | -55.30% |
| Sharpe Ratio (1Y) | -0.26 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $21.55 |
| 200-Day Average | $19.11 |
| 52-Week Range | $13.46 to $31.04 |
| RSI (14 Days) | 59.5 |
| Average Volume (20 Days) | 386.21K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.34x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 5.34x |
|---|---|
| Quick Ratio | 5.34x |
| Debt / Equity | 0.00x |
| Interest Coverage | -1307.38x |
Returns and Efficiency
Return on invested capital is -12.14% over the last 12 months, against a 5-year average of -7.98%.
| Return on Equity (ROE) | -9.29% |
|---|---|
| Return on Assets (ROA) | -8.53% |
| Return on Invested Capital (ROIC) | -12.14% |
| ROE (5Y Average) | 6.01% |
| ROA (5Y Average) | 5.39% |
| ROIC (5Y Average) | -7.98% |
| Asset Turnover | 0.29x |
| Receivables Turnover | 5.18x |
Scores
FLGT has an Altman Z-Score of 5.12, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 5.12 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $330.27M over the last 12 months is up 4.67% from the 12 months before.
| Revenue | $330.27M |
|---|---|
| Revenue Growth (YoY) | +4.67% |
| Gross Profit | $111.70M |
| Operating Income | -$129.48M |
| Pretax Income | -$98.98M |
| Net Income | -$91.98M |
| Reported EPS (TTM) | -$1.17 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 91.71% of the $1.08B in total assets.
| Cash and Equivalents | $86.79M |
|---|---|
| Total Debt | $482.00K |
| Net Cash | $86.31M |
| Net Cash Per Share | $3.12 |
| Working Capital | $311.86M |
| Shareholder Equity | $990.49M |
| Book Value Per Share | $35.81 |
| Tangible Book Value | $789.83M |
| Tangible Book Per Share | $28.55 |
| Total Assets | $1.08B |
| Total Liabilities | $94.22M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $15.83M of capital spending, operating cash flow left -$1.40M of free cash flow.
| Operating Cash Flow | $14.43M |
|---|---|
| Capital Expenditures | $15.83M |
| Free Cash Flow | -$1.40M |
| FCF Per Share | -$0.05 |
| Depreciation and Amortization | $29.84M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -39.20%, against a 5-year average of -4.99%.
| Gross Margin | 33.82% |
|---|---|
| Operating Margin | -39.20% |
| Pretax Margin | -29.97% |
| Net Margin | -27.85% |
| FCF Margin | -0.42% |
| Gross Margin (5Y Average) | 50.41% |
| Operating Margin (5Y Average) | -4.99% |
| Net Margin (5Y Average) | -4.24% |
Growth
Revenue fell 19.52% a year over 3 years, and EPS 57.76% a year.
| Revenue Growth (3Y CAGR) | -19.52% |
|---|---|
| Revenue Growth (5Y CAGR) | -5.21% |
| EPS Growth (3Y CAGR) | -57.76% |
| EPS Growth (5Y CAGR) | -45.36% |
| Book Value Per Share Growth (2Y CAGR) | -2.70% |
| Tangible Book Per Share Growth (2Y CAGR) | -2.53% |
Dividends and Yields
FLGT does not pay a dividend. Its free cash flow yield is -0.21%.
| FCF Yield | -0.21% |
|---|---|
| Buyback Yield | 9.58% |
| Shareholder Yield | 9.58% |
Peer Position
Against 11 similar companies, FLGT has the 10th highest P/S.
P/S RatioPeer median 3.4x
ROICPeer median -4.11%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +11.08%
| P/S Ratio | 2.0x vs 3.4x median |
|---|---|
| ROIC | -12.14% vs -4.11% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +4.67% vs +11.08% median |
Analyst Forecast
Consensus estimates put revenue growth at 6.71% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +6.71% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About FLGT
What is FLGT's market cap?
Fulgent Genetics has a market cap of $688.98M. Its enterprise value, which adds debt and subtracts cash, is $602.67M.
How many shares of FLGT are outstanding?
Fulgent Genetics has 27.66M shares outstanding. The count is down 10.04% from a year earlier.
Does FLGT pay a dividend?
No. Fulgent Genetics does not pay a dividend.
How much debt does FLGT have?
Fulgent Genetics has $482.00K of total debt and $86.79M of cash and equivalents, a net cash position of $86.31M.
FLGT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts